Six novel ruthenium(II)– and osmium(II)–arene
complexes
with three modified indolo[3,2-c]quinolines have
been synthesized in situ starting from 2-aminoindoloquinolines and
2-pyridinecarboxaldehyde in the presence of [M(p-cymene)Cl2]2 (M = Ru, Os) in ethanol. All complexes
have been characterized by elemental analysis, spectroscopic techniques
(1H, 13C NMR, IR, UV–vis), and ESI mass
spectrometry, while four complexes were investigated by X-ray diffraction.
The complexes have been tested for antiproliferative activity in vitro
in A549 (non-small cell lung), SW480 (colon), and CH1 (ovarian) human
cancer cell lines and showed IC50 values between 1.3 and
>80 μM. The effects of Ru vs Os and modifications of the
lactam
unit on intermolecular interactions, antiproliferative activity, and
cell cycle are reported. One ruthenium complex and its osmium analogue
have been studied for anticancer activity in vivo applied both intraperitoneally
and orally against the murine colon carcinoma model CT-26. Interestingly,
the osmium(II) complex displayed significant growth-inhibitory activity
in contrast to its ruthenium counterpart, providing stimuli for further
investigation of this class of compounds as potential antitumor drugs.